Zoetis Inc. A Stock
€99.72
Your prediction
Zoetis Inc. A Stock
Pros and Cons of Zoetis Inc. A in the next few years
Pros
Cons
Performance of Zoetis Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. A | 0.240% | -4.115% | -0.360% | -25.449% | -7.116% | -37.577% | -29.252% |
| BioMarin Pharmaceutical Inc. | -1.750% | -2.304% | -2.848% | -17.629% | -10.864% | -47.910% | -30.243% |
| Biogen Inc. | -2.650% | 4.393% | -0.913% | 49.881% | 4.972% | -40.731% | -27.562% |
| Elanco Animal Health Inc. | -0.780% | -2.370% | -8.937% | 135.986% | -0.885% | 110.958% | -26.100% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When examining the financials of Zoetis (NYSE: ZTS), a leading company in the pharmaceutical industry, a preliminary review reveals a robust picture with consistent growth in total assets over the last three years. This growth is coupled with a stable increase in shareholder equity, indicating prudent financial management and a strong balance sheet foundation. A deeper dive into the detailed numbers should provide further insights into the organization's financial health, as well as potential areas of caution.
Growing Top Line: Zoetis has demonstrated a steady increase in total revenues, with the trailing twelve-month (TTM) revenue at approximately $8.37 billion. The year-over-year quarterly revenue growth of 7.4% signals a solid capacity for expanding their market presence and sales effectiveness.
EBITDA and Operating Margins: The EBITDA and operating margins are notable strengths, with a TTM EBITDA of around $3.47 billion and an operating margin of 37.1%. These numbers suggest efficient operational management and profitability.
Comments
News
This Animal Health Stock Is Trading at Its Lowest P/E Ratio Ever
Top-notch companies don't often come cheap. Zoetis (NYSE: ZTS) is one of the world's leading animal healthcare companies. The stock has traded at an average price-to-earnings ratio of nearly 39 over
2 Healthcare Stocks to Buy and 1 to Approach With Caution
While healthcare stocks have underperformed broader equities in recent years, there are still highly attractive companies in the sector worth consideration. However, other fairly popular healthcare
2 No-Brainer Dividend Stocks to Buy in 2026
Dividend stocks are not all the same. Some will readily decrease or suspend their payouts at the first sign of trouble, while others will continue increasing them even during market downturns or